Genomma Lab Internacional traded at 15.79 this Friday November 18th, decreasing 0.06 or 0.38 percent since the previous trading session. Looking back, over the last four weeks, Genomma Lab Internacional lost 11.75 percent. Over the last 12 months, its price fell by 13.95 percent. Looking ahead, we forecast Genomma Lab Internacional to be priced at 15.35 by the end of this quarter and at 14.11 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Arca Continental 165.89 -1.07 -0.64% 28.54%
Alfa 14.15 0.05 0.35% -11.40%
Alpek 28.09 -0.81 -2.80% 35.77%
América Móvil 19.46 0.01 0.05% 6.75%
Grupo Aeroportuario del Sureste 470.93 3.81 0.82% 14.48%
Grupo Bimbo 87.56 1.89 2.21% 50.55%
Cemex Sab De Cv 4.50 0 0% -26.95%
Grupo Aeroportuario del Pacifico 318.70 -0.18 -0.06% 21.32%
Grupo Carso 86.92 1.09 1.27% 29.04%
Banorte 152.84 3.67 2.46% 11.13%
GRUMA 234.37 1.65 0.71% -6.20%
Hypermarcas 44.70 -0.76 -1.67% 54.51%
Kimberly-Clark de México 32.91 0.79 2.46% 5.04%
Genomma Lab Internacional 15.79 -0.06 -0.38% -13.95%
Odontoprev SA 8.27 0.01 0.12% -38.15%
Raia Drogasil 23.20 0.20 0.87% -0.64%

Indexes Price Day Year
IPC Mexico 51570 208.85 0.41% 1.49%

Genomma Lab Internacional
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.